The purpose of this presentation is to review current available therapies for treatment of rheumatoid arthritis and changes in the 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis, including considerations for special populations. The presenter will highlight primary literature regarding safety concerns for JAK inhibitors.